Sugi Predict

Sugi Predict / Compounds / SCHEMBL40778

SCHEMBL40778

SCHEMBL40778

COc1ccc(CN2C(=O)CCCC2=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 1/20 0.66
▸ GSK3A P49840 2/20 0.62
▸ GSK3B P49841 2/20 0.62
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ MAPT P10636 1/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ BLM P54132 1/20 0.58
▸ GAA P10253 3/20 0.54
▸ CASP3 P42574 2/20 0.54
▸ APAF1 O14727 1/20 0.54
▸ SENP8 Q96LD8 1/20 0.54
▸ SENP7 Q9BQF6 1/20 0.54
▸ SENP6 Q9GZR1 1/20 0.54
▸ KDM4E B2RXH2 2/20 0.52
▸ HTT P42858 1/20 0.52
▸ HCRTR1 O43613 1/20 0.51
▸ HCRTR2 O43614 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41389 0.93 CMA1 (0.70) CMA1GSK3AGSK3BMEN1KMT2A
SCHEMBL4321402 0.84 MEN1 (0.71) CMA1GSK3BMEN1KMT2AALDH1A1
SCHEMBL28967239 0.83 GSK3A (0.64) CMA1GSK3AGSK3BMEN1KMT2A
SCHEMBL11684109 0.82 MEN1 (0.62) CMA1GSK3AGSK3BMEN1KMT2A
SCHEMBL5449610 0.81 CMA1 (0.64) CMA1GSK3AGSK3BMEN1KMT2A
SCHEMBL25339653 0.81 GSK3A (0.59) CMA1GSK3AGSK3BMEN1KMT2A
SCHEMBL23120576 0.81 MEN1 (0.61) CMA1GSK3AGSK3BMEN1KMT2A
SCHEMBL24083677 0.80 ALDH1A1 (0.58) MEN1KMT2AALDH1A1MAPTGAA
SCHEMBL3459387 0.80 L3MBTL1 (0.64) CMA1GSK3AGSK3BMEN1KMT2A
SCHEMBL4509396 0.80 ACACB (0.64) CMA1GSK3AGSK3BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103873-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 杭州百新生物医药科技有限公司 2026-05-21 — — WO disclosed
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 — — US disclosed
WO-2025235331-A1 BIFUNCTIONAL COMPOUNDS CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY NIKANG THERAPEUTICS, INC. (US) 2025-11-13 — — WO disclosed
WO-2025235363-A1 CYCLIN-DEPENDENT KINASE 4 DEGRADERS BLUEPRINT MEDICINES CORPORATION (US) 2025-11-13 — — WO disclosed
US-20250236612-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2025-07-24 — — US disclosed
US-20250214967-A1 FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BERRYBIO SHANGHAI LTD (CN) 2025-07-03 — — US disclosed
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
WO-2025108411-A1 EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 北京沐华生物科技有限责任公司 2025-05-30 — — WO disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
US-20170182038-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2017-06-29 — — US disclosed
US-20170182038-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2017-06-29 — — US disclosed
EP-3063143-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS Novartis AG (CH) 2016-09-07 — — EP disclosed
US-9242996-B2 Aminoheteroaryl benzamides as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — US disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — US disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — US disclosed
WO-2015066188-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — WO disclosed
WO-2015066188-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — WO disclosed
WO-2012002913-A1 PROCESS OF FORMING A CYCLIC IMIDE NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2012-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 CMA1 831/4885GSK3A 845/4885GSK3B 940/4885
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS ABL1, MAP3K12, MAP3K2 CMA1 1477/4885GSK3A 325/4885GSK3B 347/4885
US-20250236612-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE CRBN, RBX1, ARAF CMA1 1710/4885GSK3A 2115/4885GSK3B 2687/4885
US-20170182038-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS ABL1, MAP3K12, MAP3K2 CMA1 1477/4885GSK3A 325/4885GSK3B 347/4885
US-20250214967-A1 FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS PTK2, CTTN, SRC CMA1 229/4885GSK3A 595/4885GSK3B 594/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 CMA1 12/4885GSK3A 2231/4885GSK3B 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.